A study of AZP-3601 for Hypoparathyroidism

The company Amolyt Pharma is commencing recruitment for the clinical trial of the AZP-3601 SAD and MAD Study in Healthy Subjects and Subjects With Hypoparathyroidism.

The condition is Chronic Hypoparathyroidism.

The trial officially began on the September 7, 2020 and is planned to complete on January 2023.

This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP) The protocol includes 3 parts: - Part A: first-in-human single ascending dose (SAD) study in healthy volunteers - Part B: multiple ascending dose (MAD) study with 2 weeks of treatment in healthy volunteers - Part C: open-label MAD study with a total treatment duration of 3 months in patients with cHP.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05239221.